HIF1α表达对晚期非小细胞肺癌患者化疗敏感性影响.docVIP

HIF1α表达对晚期非小细胞肺癌患者化疗敏感性影响 　　摘 要 目的：探讨HIF-1a表达对晚期非小细胞肺癌（NSCLC）患者的化疗敏感性。方法：选取我院收治的晚期NSCLC化疗患者92例，采用免疫组织化学法检测HIF-1a的表达，分析HIF-1a表达与化疗疗效的关系。结果：HIF-1a主要表达于肺癌细胞胞核及胞质，呈明显的异质性；HIF-1a不同表达患者间化疗有效率和疾病控制率比较差异无统计学意义（P0.05）。结论：HIF-1a的表达状态与化疗近期疗效无明显相关性，尚不能确定为晚期NSCLC患者化疗疗效的预测因子。 　　关键词 缺氧诱导因子-1a 非小细胞肺癌 化疗 敏感性 　　中图分类号：R730.23； R734.2 文献标识码：B 文章编号：1006-1533（2015）17-0041-02 　　Effect of HIF-1α expression on the chemotherapeutic sensitivity of patients with advanced non small cell lung cancer* 　　WANG Shengde1**， WEI Fenlan2（1. Department of Oncology， Railway Branch， The People’s Hospital of Yingtan City， Jiangxi Province， Yingtan 335000， China； 2. Department of Oncology， The People’s Hospital of Yingtan City， Jiangxi Province， Yingtan 335000， China） 　　ABSTRACT Objective： To investigate the effect of the expression of HIF-1a on the chemotherapeutic sensitivity of patients with advanced non-small cell lung cancer （NSCLC）. Methods： Ninety-two cases of patients with advanced NSCLC chemotherapy in our hospital were selected. The expression of HIF-1a was detected by immunohistochemistry and the relationship between the expression of HIF-1a and the efficacy of chemotherapy was analyzed. Results： HIF-1a was mainly expressed in the cytoplasm and nucleus of lung cancer cells， and its expression showed significant heterogeneity. There was no significant difference in the effective rate and the disease control rate between patients with different expression （P0.05）. Conclusion： The status of HIF-1a expression was not correlated with the short-term efficacy of chemotherapy， and is not a predictor for the efficacy of chemotherapy in patients with advanced NSCLC. 　　KEY WORDS hypoxia inducible factor-1a； non small cell lung cancer； chemotherapy； sensitivity 　　肺癌是全球累积危险性最高的恶性肿瘤，其在所有的恶性肿瘤中预后最差，而其中超过80%的肺癌为非小细胞肺癌（non-small cell lung cancer，NSCLC）[1]。恶性肿瘤细胞生长迅速、代谢快，肿瘤组织血流灌注相对减少，造成肿瘤内局部组织有显著的缺氧区域 ，且肿瘤细胞缺氧程度可在一定程度上反应恶性程度及局部复发情况[2]。本研究通过检测晚期NSCLC患者缺氧诱导因子-1a（hypoxia induction factor-1a，HIF-1a）表达水平，探讨其与化